UM
TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: Current perspectives and in silico search for small molecule binders
Shaikh F.; He J.; Bhadra P.; Chen X.; Siu S.W.
2018-06-18
Source PublicationFrontiers in Immunology
ISSN16643224
Volume9Issue:JUN
AbstractThere is now compelling evidence that TNF receptor type II (TNFR2) is predominantly expressed on CD4+Foxp3+ regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and plays a major role in the expansion and function of Tregs and MDSCs. Consequently, targeting of TNFR2 by either antagonists or agonists may represent a novel strategy in the treatment of cancer and autoimmune diseases, by downregulating or upregulating suppressor cell activity. The advance in the understanding of complex structure of TNFR2 and its binding with TNF at molecular levels offers opportunity for structure-guided drug discovery. This article reviews the current evidences regarding the decisive role of TNFR2 in immunosuppressive function of Tregs and MDSCs, and the current effort to develop novel TNFR2-targeting therapeutic agents in the treatment of cancer, autoimmune diseases, and graft-versus-host disease. To shed light on the potential TNFR2-targeting small molecules, we for the first time performed virtual screening of 400,000 natural compounds against the two TNF-binding sites, regions 3 and 4, of TNFR2. Our result showed that the top hits at region 4 had slightly higher docking energies than those at region 3. Nevertheless, free energy calculation from the TNF-TNFR2 molecular dynamics simulation revealed that the binding strength of TNF in region 3 is only one-tenth of that in region 4. This suggests that region 3 is a potentially more viable binding site to be targeted by small molecules than region 4. Therefore, the effectiveness in targeting region 3 of TNFR2 deserves further investigation.
KeywordDrug discovery MM-PBSA Regulatory T cells TNF TNF receptor type II Virtual screening
DOI10.3389/fimmu.2018.01382
URLView the original
Language英語
Fulltext Access
Citation statistics
Cited Times [WOS]:1   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionUniversity of Macau
AffiliationUniversidade de Macau
Recommended Citation
GB/T 7714
Shaikh F.,He J.,Bhadra P.,et al. TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: Current perspectives and in silico search for small molecule binders[J]. Frontiers in Immunology,2018,9(JUN).
APA Shaikh F.,He J.,Bhadra P.,Chen X.,&Siu S.W..(2018).TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: Current perspectives and in silico search for small molecule binders.Frontiers in Immunology,9(JUN).
MLA Shaikh F.,et al."TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: Current perspectives and in silico search for small molecule binders".Frontiers in Immunology 9.JUN(2018).
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Shaikh F.]'s Articles
[He J.]'s Articles
[Bhadra P.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Shaikh F.]'s Articles
[He J.]'s Articles
[Bhadra P.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Shaikh F.]'s Articles
[He J.]'s Articles
[Bhadra P.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.